Table 2. Treatment modalities of patients with stage IE–IIE1 and stage IIE2–IV POALs.

	Number of patients
Stage IE–IIE1
Chemotherapy	26
Low-dose alkylating chemotherapy with/without rituximab	8
CHOP-based chemotherapy	5
R-CHOP–based chemotherapy	13
Radiotherapy	34
2D technique	30
3D conformational technique	2
Intensity-modulated radiotherapy	1
Volumetric modulated arc therapy	1
Other treatments	31
Surgery alone	26
Radiotherapy + low-dose alkylating chemotherapy with/without rituximab	1
Radiotherapy + CHOP-based chemotherapy	2
Radiotherapy + R-CHOP–based chemotherapy	1
Intralesional rituximab injection	1
Stage IIE2–IV
Chemotherapy	11
Low-dose alkylating chemotherapy with/without rituximab	5
CHOP-based chemotherapy	2
R-CHOP-based chemotherapy	4
Combined chemotherapy and radiotherapy	5
Radiotherapy + low-dose alkylating chemotherapy with/without rituximab	3
Radiotherapy+ CHOP-based chemotherapy	2

Abbreviations: POALs, primary ocular adnexal lymphomas; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-CHOP, rituximab + CHOP.